Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5388727 | 0.93 | TACR1 (0.73) | TACR1SLC6A4 | |
| SCHEMBL6483011 | 0.93 | TACR1 (0.76) | TACR1SLC6A4 | |
| SCHEMBL3893200 | 0.89 | TACR1 (0.77) | TACR1SLC6A4 | |
| SCHEMBL13922311 | 0.84 | TACR1 (0.58) | TACR1SLC6A4 | |
| SCHEMBL5797254 | 0.81 | TACR1 (0.88) | TACR1SLC6A4 | |
| SCHEMBL6959780 | 0.81 | TACR1 (0.59) | TACR1SLC6A4 | |
| SCHEMBL13308058 | 0.81 | TACR1 (0.69) | TACR1SLC6A4 | |
| SCHEMBL3884392 | 0.81 | TACR1 (0.75) | TACR1SLC6A4 | |
| SCHEMBL13308191 | 0.81 | TACR1 (0.71) | TACR1SLC6A4 | |
| SCHEMBL3896705 | 0.81 | TACR1 (0.79) | TACR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276631-B2 | Cyclopentylamine and cyclohexylamine derivatives as NK-1/SSRI antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276631-B2 | Cyclopentylamine and cyclohexylamine derivatives as NK-1/SSRI antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276631-B2 | Cyclopentylamine and cyclohexylamine derivatives as NK-1/SSRI antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| WO-2006014664-A2 | CYCLOPENTYLAMINE AND CYCLOHEXYLAMINE DERIVATIVES AS NK-1/SSRI ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060019944-A1 | Cyclopentylamine and cyclohexylamine derivatives as NK-1/SSRI antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019944-A1 | Cyclopentylamine and cyclohexylamine derivatives as NK-1/SSRI antagonists | SLC6A4, SLC6A2, SLC6A1 | TACR1 20/4885SLC6A4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.